Novo Nordisk Study Links Semaglutide Dose Escalation to Lower MACE Risk
Patients with type 2 diabetes who increase their weekly semaglutide dose to 2 mg face a 6% lower risk of major adverse cardiovascular events compared to those who switch to tirzepatide, according to new real-world data presented at the 2026 European Association for the Study of Diabetes Annual Meeting in Milan.



























